Morgan Stanley: Space is the "ultimate backyard" for computing power, maintains "Overweight" rating on SpaceX (SPCX.US)
Morgan Stanley maintains an "Overweight" rating on SpaceX with a target price of $300, stating that space is the ultimate scenario for AI computing power and that the renaming to SpaceXSI reflects ambitions for superintelligence.
According to news from Zhihu Finance APP, Morgan Stanley released a research report maintaining its “Overweight” rating on SpaceX (SPCX.US) with a target price of $300, which is close to 90% upside from the closing price of $158.96 on October 2. Analyst Adam Jonas and his team presented an even broader view: space is becoming the ultimate arena for transforming energy into intelligence in the AI era.
Morgan Stanley pointed out that space is the ideal place to convert energy into intelligence at scale—it’s like a “huge, cold, and sun-drenched backyard.” As ground-based data centers are running into power constraints and site selection controversies, this logic is gaining traction.
The report also highlighted a new phenomenon: “Space Washing.” As the anti-data center movement gains momentum, more and more companies are beginning to extol the virtues of space, shifting the computational power narrative to orbit. Morgan Stanley has noticed that several tech giants are now making clear moves in the space AI infrastructure realm; SpaceX is not the only major player making heavy bets in this area.
Renamed to SpaceXSI: The “Super Intelligence” Ambition Behind a Letter
Musk has announced the renaming of his AI division from SpaceXAI to SpaceXSI—shifting from “Artificial Intelligence (AI)” to “Super Intelligence (SI).” Morgan Stanley reminds investors to reflect on the deeper significance: this move echoes Trump’s executive order—which changed the term “Artificial Intelligence” to “Super Intelligence” in non-statutory documents. Previously, Musk made a high-profile appearance during his recent state visit to China and was just appointed by Defense Secretary Hegseth as co-head of “Project Meridian.” Sharing this title with him are Anduril CEO Palmer Luckey and former House Speaker Newt Gingrich.
Morgan Stanley makes it clear that what seem like trivial and unrelated events actually form a coherent thread: the forces represented by the “Muskonomy” are now seen as key pieces in America’s national strategy to rebuild domestic manufacturing and defense capabilities.
Valuation Breakdown: How the $300 Target Was Calculated
Morgan Stanley used the Sum-of-the-Parts (SOTP) method, splitting SpaceX into four segments: Space business $8, Connectivity business (Starlink) $118, X and Grok $8, and Enterprise AI $165. Of these, Enterprise AI alone accounts for more than half the value, though it’s been discounted by 50% due to execution risks.
From “the last mile of AI” to “the Super Intelligence renaming game,” what Morgan Stanley’s report really aims to say is this: as the physical limits of computational power emerge on earth, space becomes not just a narrative of aspiration, but the next main battlefield for AI infrastructure—and SpaceX stands at the starting line of this track.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Caribou shares fall after discontinuing cell therapy program and launching strategic review
On October 6th, shares of biotech company Caribou Biosciences (CRBU.O) fell by 36.1% in after-hours trading to $0.73. The company announced it is exploring potential sale, merger, or other options to unlock shareholder value. Caribou plans to discontinue the development of its experimental cell therapy vispa-cel for a certain blood cancer, as well as CB-011 for treating the bone marrow cancer—multiple myeloma. The company stated that vispa-cel is ready for clinical trials, and it has reached an agreement with the FDA on the design for late-stage clinical trials. However, the difficult financing environment for allogeneic CAR-T therapies has made it challenging to raise the necessary funds to advance these projects. Caribou also intends to lay off employees and cut costs; according to its report, as of June 30, 2026, the company held $113.8 million in cash, cash equivalents, and marketable securities. As of the previous trading day’s close, the stock had fallen about 29% year-to-date. (For the convenience of non-English speakers, Reuters provides automated translation of its reports into several languages. As automated translations may contain errors or lack context, Reuters does not guarantee the accuracy of automated translation texts and provides them solely for reader convenience. Reuters assumes no liability for any harm or loss from use of the automated translation feature.)
VWO ETF Closes Flat
This article was automatically generated using Dow Jones technology. Shares of Vanguard FTSE Emerging Markets ETF were flat at $60.62 Tuesday on what proved to be an overall favorable trading session for the U.S. stock market, with the S&P 500 Index rising 0.6% to 7,818.93. This was the fund's third consecutive day of gains. The ETF's shares closed 1.5% below the 52-week high of $61.53 seen on September 4, 2026. Trading volume was 4,661,177, compared to the 65-day average trading volume of 7,016,590. As of October 5, the fund's net asset value totaled $60.76 per share. Data source: Dow Jones Market Data, FactSet (END) Dow Jones Newswires October 06, 2026 16:37 ET (20:37 GMT)
Novavax Inc. Stock Slides 9.9%, Underperforms Peers
This article was automatically generated by Dow Jones using technology from Automated Insights. Shares of Novavax Inc. shed 9.9% to $11.32 on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index rising 0.4% to 27,599.79 and the Dow Jones Industrial Average rising 0.5% to 51,521.28. Novavax Inc. closed 15.4% below its 52-week high of $13.39, which the company achieved on October 5th. The stock underperformed when compared to some of its peers, as Johnson & Johnson rose 0.7% to $254.78, Pfizer Inc. rose 0.3% to $27.50, and Merck & Co. Inc. rose 1.72% to $141.94. Trading volume totaled 19.3 million, compared to the 50-day average of 5.3 million. Data source: Dow Jones Market Data, FactSet (END) Dow Jones Newswires October 06, 2026 16:33 ET (20:33 GMT)
Evogene announces special shareholder meeting
Evogene will hold a special general meeting of shareholders in Rehovot, Israel on Nov. 10, 2026. Shareholders will vote on electing Oz Adler and Dr. Adi Zuloff-Shani to the board. Ballots will also cover the election of Itay Maroz and Shahar Zadok, subject to approval of a cooperation agreement. The meeting will also vote on a cooperation agreement between Evogene and L.I.A. Pure Capital and Invest-Pro Shukai Hon. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evogene Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-004722), on October 06, 2026, and is solely responsible for the information contained therein.
Crypto prices
More
